Skip to main content

Table 4 Stratified effects of metabolic syndrome on colon cancer and rectal cancer risks by VEGF 3′-UTR variants

From: Interplay between 3′-UTR polymorphisms in the vascular endothelial growth factor (VEGF) gene and metabolic syndrome in determining the risk of colorectal cancer in Koreans

     CC risk RC risk
Genotype/Haplotype Model Subgroup Wild type AOR (95% CI) p AOR (95% CI) p
VEGF 1451C > T Additive Without MetS CC 1.12 (0.80 - 1.54) 0.513 1.42 (0.99 - 2.03) 0.055
   With MetS CC 0.89 (0.50 - 1.59) 0.701 1.44 (0.77 - 2.67) 0.255
  Dominant Without MetS CC 1.18 (0.79 - 1.77) 0.416 1.67 (1.07 - 2.61) 0.023
   With MetS CC 0.78 (0.41 - 1.49) 0.456 1.44 (0.74 - 2.78) 0.280
  Recessive Without MetS CC 0.99 (0.41 - 2.40) 0.985 1.09 (0.41 - 2.87) 0.868
   With MetS CC 3.07 (0.30 - 31.00) 0.342 2.14 (0.13 - 35.71) 0.595
VEGF 1612G > A Additive Without MetS GG 0.73 (0.49 - 1.07) 0.105 0.81 (0.53 - 1.24) 0.328
   With MetS GG 1.10 (0.61 - 2.02) 0.746 0.97 (0.50 - 1.87) 0.928
  Dominant Without MetS GG 0.71 (0.46 - 1.09) 0.117 0.69 (0.42 - 1.14) 0.148
   With MetS GG 1.13 (0.60 - 2.14) 0.704 0.93 (0.46 - 1.89) 0.850
  Recessive Without MetS GG 0.58 (0.15 - 2.17) 0.416 1.51 (0.49 - 4.61) 0.469
   With MetS GG 0.78 (0.05 - 13.40) 0.867 1.72 (0.10 - 28.53) 0.705
VEGF 1725G > A Additive Without MetS GG 1.34 (0.72 - 2.49) 0.360 1.82 (0.95 - 3.48) 0.072
   With MetS GG 1.37 (0.62 - 2.98) 0.435 1.20 (0.51 - 2.85) 0.672
  Dominant Without MetS GG 1.34 (0.72 - 2.49) 0.360 1.82 (0.95 - 3.48) 0.072
   With MetS GG 1.37 (0.62 - 2.98) 0.435 1.20 (0.51 - 2.85) 0.672
  Recessive Without MetS GG - - - -
   With MetS GG - - - -
VEGF 1451C/1612G/1725G   Without MetS Others 1.06 (0.80 - 1.40) 0.697 0.87 (0.63 - 1.19) 0.375
   With MetS Others 0.95 (0.61 - 1.49) 0.840 0.80 (0.50 - 1.28) 0.354
VEGF 1451T/1612G/1725G   Without MetS Others 1.13 (0.80 - 1.58) 0.495 1.45 (1.00 - 2.09) 0.047
   With MetS Others 0.90 (0.51 - 1.58) 0.705 1.36 (0.77 - 2.42) 0.292
VEGF 1451C/1612A/1725G   Without MetS Others 0.61 (0.38 - 0.97) 0.038 0.48 (0.26 - 0.86) 0.015
   With MetS Others 1.04 (0.48 - 2.25) 0.930 0.87 (0.37 - 2.08) 0.760
VEGF 1451C/1612A/1725A   Without MetS Others 1.09 (0.58 - 2.05) 0.795 1.75 (0.93 - 3.28) 0.081
   With MetS Others 1.13 (0.53 - 2.43) 0.745 1.08 (0.47 - 2.51) 0.854
  1. Adjusted odds ratio (AOR), Confidence interval (CI), Metabolic syndrome (MetS), Colon cancer (CC), Rectal cancer (RC), Vascular endothelial growth factor (VEGF). AORs and p values were adjusted by age and gender.